Last reviewed · How we verify

Col-Probenecid — Competitive Intelligence Brief

Col-Probenecid (probenecid) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: probenecid. Area: Immunology.

marketed probenecid Carbonic anhydrase 9 Immunology Live · refreshed every 30 min

Target snapshot

Col-Probenecid (probenecid) — Pfizer Inc.. ORLYNVAH combines sulopenem etzadroxil, a penem antibacterial, with probenecid to increase sulopenem's plasma concentration by inhibiting its renal clearance.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Col-Probenecid TARGET probenecid Pfizer Inc. marketed probenecid Carbonic anhydrase 9 1951-01-01
Siklos Siklos Theravia marketed Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Xromi Xromi Nova Laboratories Limited marketed Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Hydroxycarbamide Hydroxycarbamide University of Birmingham phase 3 Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (probenecid class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Col-Probenecid — Competitive Intelligence Brief. https://druglandscape.com/ci/probenecid. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: